# Helen Kim

> Helen Kim is a Series A investor at Vida Ventures backing Biotechnology and Health Care. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Vida Ventures](https://shizune.co/investors/profile/vida-ventures)
- Location: Santa Monica, United States
- Total investments: 8
- Last investment: Jan 2026
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/helen-s-kim-1a6700/

Helen Kim is a Series A investor at Vida Ventures in Santa Monica focused on Biotechnology and Health Care. Helen S. Kim is based out of Santa Monica, California and is the Senior Managing Director of Vida Ventures. Helen previously worked at The Column Group as a partner. Helen S. Kim attended the University of Chicago. Helen S. Kim has received Women’s Leadership Awards in their career.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 50% |
| Health Care | 3 | 38% |
| Medical | 2 | 25% |
| Biopharma | 2 | 25% |
| Therapeutics | 2 | 25% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 50% |
| Series B | 2 | 25% |
| Series C | 1 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Poplar Therapeutics | Poplar Therapeutics anti-IgE therapy treats atopic diseases such as food allergy, allergic asthma, and atopic dermatitis. | $50M | Series A | Jan 07, 2026 |  |
| Protego Biopharma | Protego Biopharma develops therapeutics based on the clear human genetic link, excellent human safety profile, proof-of-principle efficacy. The company was founded in 2011 and is headquartered in San Diego, California. | $130M | Series B | Dec 01, 2025 |  |
| ReCode Therapeutics | ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and developfirst-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations.ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing.The company was founded in 2015 and is based in Dallas, Texas. | $50M | Series B | Sep 19, 2023 |  |
| ReCode Therapeutics | ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and developfirst-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations.ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing.The company was founded in 2015 and is based in Dallas, Texas. | $80M | Series B | Oct 21, 2021 |  |
| Protego Biopharma | Protego Biopharma develops therapeutics based on the clear human genetic link, excellent human safety profile, proof-of-principle efficacy. The company was founded in 2011 and is headquartered in San Diego, California. | $51M | Series A | Oct 19, 2021 |  |
| IconOVir Bio | IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer. | $77M | Series A | Jan 05, 2021 |  |
| ReCode Therapeutics | ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and developfirst-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations.ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing.The company was founded in 2015 and is based in Dallas, Texas. | $80M | Series A | Mar 26, 2020 |  |
| PACT Pharma | Pact Pharma is a developer of personalized adoptive T cell therapies designed for the eradication of solid tumors.The company's therapies help in the identification of neo-epitopes that serve as private mutations for each patient's cancer as well as creates an opportunity to engineer autologous T cells that target and kill tumorsexpressing these neo-antigens, enabling physicians to recognize and remove each patient's cancer cells. | $75M | Series C | Jan 11, 2020 |  |

8 of 8 investments shown.

## Co-investors
- [MPM Capital](https://shizune.co/investors/profile/mpm-capital) — VC Fund, 5 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 3 deals together
- [OUP (Osage University Partners)](https://shizune.co/investors/profile/osage-university-partners) — VC Fund, 3 deals together
- [Colt Ventures](https://shizune.co/investors/profile/colt-ventures) — VC Fund, 2 deals together
- [Droia Ventures](https://shizune.co/investors/profile/droia) — VC Fund, 2 deals together
- [EcoR1 Capital](https://shizune.co/investors/profile/ecor1-capital) — VC Fund, 2 deals together

## About Vida Ventures

VC Fund · Boston, United States

Vida Ventures’ mission is to bring science to life by advancing transformative biomedical innovations that have the potential to make a meaningful impact on the lives of patients. They want to do well by doing good for others. Vida Ventures is a bicoastal life sciences company building and investment firm, founded in 2017 by a group of scientists,physicians, entrepreneurs, and investors who are passionate about building and funding breakthroughs in biomedicine .

5 contacts available at Vida Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Fred Cohen | Co-Founder & Sr. Managing Director | https://shizune.co/investors/profile/fred-cohen |
| Helen Kim | Senior Managing Director | https://shizune.co/investors/profile/helen-s-kim-1469 |
| Mark Springel | Associate | https://shizune.co/investors/profile/mark-springel |
| Arie Belldegrun | Co-Founder & Senior Managing Director; Founding Partner | https://shizune.co/investors/profile/arie-belldegrun |
| Arjun Goyal | Co-Founder and Managing Director | https://shizune.co/investors/profile/arjun-goyal |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Helen Kim invest in?

Helen Kim invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Helen Kim last invest?

The most recent investment recorded for Helen Kim closed in Jan 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co